Dermira (DERM) Climbs 48% After Reporting Positive Topline Results from Phase 2b Study of Lebrikizumab in Patients with Atopic Dermatitis
Tweet Send to a Friend
Dermira (NASDAQ: DERM) Climbs 48 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
